Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)ā¢ Click on a phase to view related trials
A Study of OV101 in Individuals With Angelman Syndrome (AS)
- Conditions
- Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Ovid Therapeutics Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT04106557
- Locations
- š³š±
Ovid Therapeutics Investigative Site, Rotterdam, Netherlands
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Healx AI
- Target Recruit Count
- 141
- Registration Number
- NCT03882918
- Locations
- š®š±
Ovid Therapeutics Investigative Site, Ramat Gan, Israel
A Study of OV101 in Individuals With Fragile X Syndrome
- Conditions
- Fragile X Syndrome (FXS)
- Interventions
- Drug: OV101 (gaboxadol)
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Ovid Therapeutics Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03697161
- Locations
- šŗšø
Ovid Therapeutics Investigative Site, Nashville, Tennessee, United States
Single Dose Pharmacokinetic (PK) Study
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Ovid Therapeutics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03109756
- Locations
- šŗšø
Ovid Therapeutics Investigative Site, Nashville, Tennessee, United States
A Study in Adults and Adolescents With Angelman Syndrome (STARS)
- Conditions
- Angelman Syndrome
- Interventions
- Drug: OV101 regimen 2Other: PlaceboDrug: OV101 Regimen 1
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Healx AI
- Target Recruit Count
- 88
- Registration Number
- NCT02996305
- Locations
- š®š±
Ovid Therapeutics Investigative Site, Ramat Gan, Israel
News
Ovid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 Million
Ovid Therapeutics has entered into a definitive agreement with Immedica Pharma AB to sell its future royalty rights for ganaxolone sales outside China for $7 million in cash.
FDA Leadership Shakeup: Peter Marks' Forced Resignation Sends Shockwaves Through Biopharma Industry
Peter Marks, head of FDA's Center for Biologics Evaluation and Research since 2016, was forced to resign after refusing to support HHS Secretary Robert F. Kennedy Jr.'s vaccine safety claims.
Ovid Therapeutics Advances Novel Neurological Drug Pipeline with Key Clinical Milestones Expected in 2025-2026
Ovid Therapeutics is advancing its pipeline of neurological treatments, with topline results from OV329's Phase 1 study for drug-resistant epilepsies expected in Q3 2025 and first-in-human studies for KCC2 activator OV350 initiated in Q1 2025.
Global Clinical Trials for Dravet Syndrome Reviewed in 2024
ā¢ A new report offers an overview of the clinical trial landscape for Dravet Syndrome, also known as Severe Myoclonic Epilepsy of Infancy, providing key data and analysis. ā¢ The review includes data on trial numbers, average enrollment, and top countries involved, segmented by region, phase, status, endpoints, and sponsor type. ā¢ Key companies like Jazz Pharmaceuticals, UCB, Takeda, and others are profiled, with details on their ongoing trials and prominent drugs in development for Dravet Syndrome. ā¢ The report identifies trends in clinical trial enrollment over the past five years and highlights recent news related to Dravet Syndrome research and development.